Paris, France, Boston, USA, June 15, 2023 – TISSIUM, a private medtech specializing in the development of programmable biomorphic polymers for tissue reconstruction, announces it has obtained a non-dilutive financing of €4.2 million from Bpifrance as part of the “France 2030” plan to extend its production capacity for “large volume” syringes.
As TISSIUM continues to enrich its product platform in new therapeutic indications, it will continue its rapid international expansion through its in-house production and state-of-the-art industrial capabilities, which will be extended with this new funding.
Christophe Bancel, CEO of TISSIUM, declares: “This new financing demonstrates the confidence of the French State in the solidity of our project and the potential of our solutions. It will allow us to rapidly increase our production capacity, but also help us enrich our platform. We will thus be able to meet the demand of surgeons and allow a large number of patients to benefit from our products once they are approved by the regulatory authorities. This will also contribute to the reindustrialization and the development of employment in France”.
